전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,369 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

FGFR4-CAR T Cells (FGFR4-CAR T Cells)

Rhabdomyosarcoma · Rhabdomyosarcoma

#Rhabdomyosarcoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleWashington Research FoundationPhase 1

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

Advanced Osteosarcoma; Recurrent Osteosarcoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 2

adalimumab (Humira, FITC-Adalimumab)

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Phase2#monoclonal-antibody#AbbVie
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

FL33-03 CAR-T therapy (FL33-03 CAR-T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleInstitut für Klinische Krebsfor…Phase 3

trastuzumab (Herceptin, FLOT + Herceptin/Pertuzumab)

Stomach Cancer; Gastroesophageal Junction Cancer · Stomach Cancer

#StomachCancer#Antibody#Phase3#monoclonal-antibody#GastroesophagealJunctionCancer+1
Trials 1Status Active
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

FOLR1 CAR T-cells (FOLR1 CAR T-cells)

Recurrent Childhood Acute Myeloid Leukemia; Refractory Childhood Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

3 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (3 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleNanogen Pharmaceutical Biotechn…Phase 3

Faceptor (Faceptor)

Breast Cancer Metastatic; Breast Cancer Recurrent · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase3#monoclonal-antibody#BreastCancerRecurrent+1
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

Faminitib or bevacizumab (Faminitib or bevacizumab)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#antibody-drug-conjugate#OvarianNeoplasms+2
Trials 1Status Discontinued
AntibodyLimited DatastaleHI-Bio, A Biogen CompanyPhase 2

Felzartamab (Felzartamab)

Immunoglobulin A (IgA) Nephropathy · Immunoglobulin A (IgA) Nephropathy

#ImmunoglobulinAIgANephropathy#Antibody#Phase2#monoclonal-antibody#HI-Bio
Trials 1Status Active
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued

75 / 119 pages

← PreviousNext →